VCYT 250516 45.00P(VCYT250516P45000) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

Clear

All

Quotes

News

Learn

Help

All

News

Announcements

No matches yet

Operations too frequent. Please try again later.

Please check network settings and try again Refresh Refresh

History record

VCYT250516P45000

Watchlist

0.00
0.000.00%

15min DelayClose May 1 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Earnings Preview: Veracyte to Report Financial Results Post-market on May 07
Moomoo News21:00 ET
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms
BenzingaApr 26 03:39 ET
Express News | Veracyte Inc - Decipher Prostate Metastatic Test Orders Begin June 2025
ReutersApr 25 07:04 ET
Express News | Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients With Metastatic Prostate Cancer
ReutersApr 25 07:00 ET
Veracyte Says At Least 18 Abstracts Focused On Decipher Prostate And Decipher Bladder Genomic Classifiers Will Be Presented At AUA 2025
BenzingaApr 22 09:02 ET
Veracyte Says Data From Decipher Prostate Genomic Classifier Are Linked to Real-World Data in NCI's SEER Specialized Database Release
BenzingaApr 21 16:07 ET

Comments

Teddy123

Apr 22 21:05

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

$Veracyte (VCYT.US)$
Breakthrough Cancer Insights: 18 New Studies Confirm Veracyte Decipher Test's Power in Prostate and Bladder Cancer

Teddy123

Mar 26 14:59

New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

$Veracyte (VCYT.US)$
Revolutionary Blood Test Detects Cancer Return 3 Months Earlier Than Imaging

Teddy123

Mar 20 08:20

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

$Veracyte (VCYT.US)$
Veracyte's Cancer Detection Tests Prove Powerful in Major Clinical Studies - New Product Coming

Lnova

Feb 16 14:46

Artisan Partners Limited Partnership 5,402,362 shares, 8.5%
$Veracyte (VCYT.US)$
has options
nfa

Veracyte | SCHEDULE 13G/A: Others

Teddy123

Feb 14 22:08

Medical Research analysis

$Veracyte (VCYT.US)$
The extensive validation of Veracyte's Decipher platform at ASCO GU 2025, supported by 17 abstracts and publication in Annals of Oncology, represents a significant strengthening of the company's market position in cancer diagnostics. The data demonstrates three important commercial advantages:
First, the Decipher Prostate test's ability to predict treatment response in the NRG Oncology/RTOG 0534 trial provides a clear clinical utility case for insura...